Ventyx Biosciences Inc (VTYX)
4.71
-0.14
(-2.89%)
USD |
NASDAQ |
May 06, 16:00
4.725
+0.02
(+0.32%)
After-Hours: 20:00
Ventyx Biosciences Cash from Investing (TTM): 100.94M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 100.94M |
September 30, 2023 | -86.02M |
June 30, 2023 | -60.75M |
March 31, 2023 | -77.32M |
December 31, 2022 | -74.93M |
Date | Value |
---|---|
September 30, 2022 | -77.18M |
June 30, 2022 | -214.51M |
March 31, 2022 | -232.77M |
December 31, 2021 | -214.36M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-232.77M
Minimum
Mar 2022
100.94M
Maximum
Dec 2023
-104.10M
Average
-77.32M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Anavex Life Sciences Corp | -- |
CERo Therapeutics Holdings Inc | -- |
Avinger Inc | -0.008M |
Checkpoint Therapeutics Inc | -- |
RAPT Therapeutics Inc | 104.13M |